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Abstract
Background Polypharmacy in older patients can lead to potentially inappropriate prescribing. The risk of the latter calls for 
effective medication review to ensure proper medication usage and safety. Objective Provide insight on the similarities and 
differences of medication review done in multiple ways that may lead to future possibilities to optimize medication review. 
Setting This study was conducted in Zuyderland Medical Centre, the second largest teaching hospital in the Netherlands. 
Method This descriptive study compares the quantity and content of remarks identified by medication review performed by 
a geriatrician, outpatient pharmacist, and Clinical Decision Support System. The content of remarks is categorized in seven 
categories of possible pharmacotherapeutic problems: ‘indication without medication’, ‘medication without indication’, 
‘contra-indication/interaction/side-effect’, ‘dosage problem’, ‘double medication’, ‘incorrect medication’ and ‘therapeutic 
drug monitoring’. Main outcome measure Number and content of remarks on medication review. Results The Clinical 
Decision Support System (1.8 ± 0.8 vs. 0.9 ± 0.9, p < 0.001) and outpatient pharmacist (1.8 ± 0.8 vs. 0.9 ± 0.9, p = 0.045) 
both noted remarks in significantly more categories than the geriatricians. The Clinical Decision Support System provided 
more remarks on ‘double medication’, ‘dosage problem’ and ‘contraindication/interaction/side effects’ than the geriatrician 
(p < 0.050), while the geriatrician did on ‘medication without indication’ (p < 0.001). The Clinical Decision Support System 
noted significantly more remarks on ‘contraindication/interaction/side effects’ and ‘therapeutic drug monitoring’ than the 
outpatient pharmacist, whereas the outpatient pharmacist reported more on ‘indication without medication’ and ‘medication 
without indication’ than the Clinical Decision Support System (p ≤ 0.007). Conclusion Medication review performed by a 
geriatrician, outpatient pharmacist, and Clinical Decision Support System provides different insights and should be combined 
to create a more comprehensive report on medication profiles.
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Impacts on practice
• The Clinical Decision Support System is particularly 
potent in indicating ‘contraindications/interactions/side 
effects’ and can help reduce potentially inappropriate 
prescribing.
• Combined medication review by a geriatrician, an 
outpatient pharmacist, and a Clinical Decision Sup-
port System has different perspectives and should be 
combined to ensure adequate medication usage and 
safety. Moreover it could potentially reduce (increas-
ing) health care costs.
• Benzodiazepines, betahistin, opiates, antihistamines, 
antihypertensive agents and non-steroidal-anti-inflam-
matory drugs provide for the majority of drug related 
problems in the Dutch hospital setting.
Introduction
As the general population ages, the number of older 
patients (≥ 65 years) in hospitals increases [1–5]. These 
(ill) older patients make for a vulnerable group. This 
vulnerability is caused by factors such as reduced self-
reliance due to multimorbidity, reduced cognitive skills, 
malnutrition, and physical constraints [6–8]. Because of 
their multimorbidity, polypharmacy (≥ 5 medicines) is 
common in this group. Besides their intended effects, these 
medicines have potential risks and adverse effects. The 
likelihood of the latter is significantly increased in older 
patients due to their vulnerability and altered pharmacoki-
netics and dynamics [9]. Prescribing medication in older 
patients is therefore complex and poses challenges.
The risk of potentially inappropriate prescribing (PIP) 
calls for effective methods to ensure adequate medication 
usage and safety. One of these methods is proper collabo-
ration and coordination between patient or caregiver, phy-
sicians, pharmacists and other healthcare professionals. 
However, involvement of different physicians can cause 
a variety of medication prescriptions, increasing the risk 
of interactions and adverse effects if this is not taken 
into account whilst prescribing [10]. Geriatricians care 
for nearly the full spectrum of diseases seen in general 
medicine, taking into account the complexities in geri-
atric medicine. Therefore they often perform medication 
review: a structured evaluation of a patient’s medicines 
with the aim of optimising medicines use and improving 
health outcomes [11].
In the Netherlands medication review is mainly 
performed by geriatricians, pharmacists and general 
practitioners, using the STRIP (Systematic Tool to Reduce 
Inappropriate Prescribing) method. The national guideline 
focuses on analysing potential pharmacotherapeutic prob-
lems, including: undertreatment, ineffective medication, 
overtreatment, (potential) adverse effects, contraindica-
tion, interaction and dosage problem [12]. The STOPP/
START (Screening Tool of Older Persons’ potentially 
inappropriate Prescriptions/Screening Tool to Alert Doc-
tors to the Right Treatment) criteria [13, 14] are part of 
this analysis. The STOPP criteria describe PIP in older 
patients, whereas the START criteria provide guidance in 
prescribing medication in order to avoid undertreatment.
Although periodic medication review can lead to preven-
tion of PIP [15, 16], there is no consensus on what such 
a review should comprise. In recent years, it has become 
apparent that Clinical Decision Support Systems (CDSSs) 
can provide support in medication reviews and could possi-
bly reduce medication-related errors [17–19]. CDSSs could 
therefore contribute in improving quality of care and out-
comes in older patients.
Moreover, pharmacists have extensive knowledge on 
pharmacokinetics and dynamics and could provide valuable 
insights in performing medication review. Hence, incorpo-
rating pharmacists in the process of medication review could 
improve prescribing appropriateness [20, 21].
Aim of the study
In this observational study, the similarities and differences 
of medication reviews performed by a geriatrician, an out-
patient pharmacist, and the hospital’s CDSS are described. 
We compare the quantity and types of possible pharmaco-
therapeutic problems identified by these three different per-
spectives. A better understanding of these perspectives could 
lead to possible optimization of medication review.
Ethics approval
The study was approved by the Zuyderland Medical Ethical 
Testing Committee (METC) (study 16-N-115) and obtaining 
informed consent was waived.
Method
Setting
This study was conducted in Zuyderland Medical Centre, a 
large teaching hospital in the Netherlands that treats roughly 
190,000 patients per year. The hospital is located in one of 
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the fastest aging regions [22], hence many older patients 
are treated.
Clinical rule reporter (CRR)
The CRR is a CDSS that is developed in the Zuyderland 
Medical Centre. It currently reviews medication profiles of 
all hospitalized patients. In addition, data on medication 
profiles of specific outpatient populations can be imported 
and reviewed. The system has access to all medication 
prescriptions of the past few months, through a digital net-
work of regional pharmacies. Additionally, it has access to 
patient characteristics such as age, gender, co-medication 
and laboratory values. There is no digital link between the 
CRR and general practitioner data or medical history. The 
CRR combines information to obtain specific advice based 
on clinical rules (i.e. algorithms). These are clearly defined 
rules, that include the latest version of the STOPP/START 
criteria [13, 14] and utilize triggers to identify the need to 
discontinue or add medication, or aim for dose-reduction. 
During this study, 293 rules were operational, which is on 
top of medication surveillance for high-risk medication. 
The CRR reports by means of ‘green’ (no additional action 
needed) or ‘red’ (definite action needed) alerts. This implies 
the CRR checks for certain conditions by means of clinical 
rules and if this condition is met, a ‘green’ alert is noted 
[e.g. the use of proton pump inhibitors (PPIs) when using 
acetylsalicylic acid (ASA) at elder age]. On the other hand, 
hazardous combinations or an increased risk of adverse 
events, will generate a ‘red’ alert (e.g. the use of metformin 
in renal failure). Both ‘green’ and ‘red’ alerts are considered 
relevant because medication review by a physician or phar-
macist should also comprise these checks. The clinical rules 
are updated based on insights from professional networks, 
research and guidelines.
Data collection and analysis
Between May and July 2016, all new patients to the geri-
atric outpatient clinic were included (n = 200). There were 
no specific in- or exclusion criteria. Patient characteristics 
(i.e. gender, age, number of medications, and medication 
categorized to ATC (Anatomical Therapeutic Chemical 
Classification System) code [23]) were extracted from the 
electronic patient file and medication system. Based on the 
information available in the patient’s file, one of seven geri-
atricians performed a medication review (n = 200) on the day 
of visit using the national guideline [12]. The geriatricians 
were unaware of the study as medication review is consid-
ered part of the standard comprehensive geriatric assessment 
(CGA). The remarks on medication review were retrieved 
from the patient’s file by the research team. Furthermore, 
an outpatient pharmacist reviewed the patient’s medication 
independently in a consultation prior to the appointment at 
the geriatrician while having access to the same informa-
tion as the geriatricians. These reviews were also guided by 
the previously mentioned national guideline. The remarks 
on medication review by the pharmacist were sent to the 
research team. Due to logistical challenges, 54 out of 200 
medication profiles were reviewed by the pharmacist. These 
patients were selected randomly, based on presence of the 
pharmacist that day. Finally, 197 out of 200 medication pro-
files were assessed by the CDSS (3 patients did not consent 
to the digital exchange of data on medication use).
The remarks of the geriatrician, outpatient pharmacist and 
reports from the CDSS were categorized by the research 
team in seven pre-established categories (Table 1) that were 
used in previous research [24] and are based on possible 
pharmacotherapeutic problems [12]. Next, the quantity 
and content of remarks in these categories was compared. 
Moreover, the pharmacist focused on efficiency of medica-
tion prescriptions, drug adherence, use of over-the-counter 
(OTC) medications, and presence of a medication organ-
izer or blister pack in addition to the seven categories. Drug 
adherence was assessed based on questions to patient or 
caregiver whether medication was used as prescribed and if 
Table 1  Overview of remarks per patient by the geriatrician, outpa-
tient pharmacist and CDSS
SD standard deviation
a Statistically significant for comparison between geriatrician and out-
patient pharmacist
b Statistically significant for comparison between geriatrician and 
CDSS
c Statistically significant for comparison between outpatient pharma-
cist and CDSS
Geriatrician
(n = 200)
Outpatient 
pharmacist
(n = 54)
CDSS
(n = 197)
Total number of remarks 263 145 945
Characteristic (mean ± SD)
 Number of remarks 1.3 ± 1.5 2.7 ± 1.4 4.6 ± 3.6b
 Number of different cat-
egories
0.9 ± 0.9 1.8 ± 0.8a 1.8 ± 0.8b
Categories (mean ± SD)
 Indication without medica-
tion
0.9 ± 1.0 1.3 ± 1.0ac 0.7 ± 1.0
 Medication without indica-
tion
0.1 ± 0.6b 0.6 ± 0.8ac 0.0 ± 0.0
 Contra-indication/interac-
tion/adverse effect
0.0 ± 0.2 0.3 ± 0.5a 3.5 ± 2.7bc
 Dosage problem 0.2 ± 0.5 0.4 ± 0.7a 0.3 ± 0.5b
 Double medication 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.0
 Incorrect medication 0.0 ± 0.1 0.0 ± 0.0 0.0 ± 0.0
 Therapeutic drug monitor-
ing
0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.3bc
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there were any cognitive or practical barriers. It is important 
to specify that the geriatrician and outpatient pharmacist did 
not consult the CDSS for their patients. The information col-
lected on medication review was shared in the patient’s file, 
accessible to all disciplines.
Statistical analysis was performed with IBM SPSS Statis-
tics 23. Paired sampled T test was used to analyse differences 
in number and type of remarks between the geriatricians, 
outpatient pharmacist and CDSS. In these comparative anal-
ysis the corresponding sample size as mentioned above, was 
used. The Bonferroni correction was applied to address the 
problem of multiple comparisons. Continuous variables are 
reported as means (± standard deviation (SD)) and categori-
cal variables as percentages.
Results
In total 200 patients were included of which 118 (59%) were 
female. The mean age of the population was 82 (± 6) years. 
The mean number of medications used was 8 (± 4) includ-
ing OTC and as required medications. Categorizing medi-
cation to ATC code, we see ≥ 40% of the patients use PPIs, 
vitamin D, anticoagulants, diuretics, beta blocking agents, 
agents acting on the renin–aldosterone–angiotensin system 
(RAAS), and statins (“Appendix 1”). More than 20% of the 
patients used drugs for constipation, mineral supplements 
(mainly calcium), cardiac therapy, analgesics other than opi-
oids and hypnotics (mainly benzodiazepines).
The total number of remarks by the geriatrician was 263 
(n = 200) compared with 145 (n = 54) by the outpatient phar-
macist and 945 (n = 197) by the CDSS (809 ‘green’ and 136 
‘red’ reports). The mean number of remarks per patient by 
the geriatrician was 1.3 (± 1.5), compared with 2.7 (± 1.4) 
by the outpatient pharmacist and 4.6 (± 3.6) by the CDSS 
(p < 0.05). The outpatient pharmacist thus had twice as much 
remarks about the same patient than the geriatrician. In addi-
tion, the CDSS provides 1.8 times more remarks than the 
outpatient pharmacist and 3.6 times more than the geriatri-
cian (both p < 0.001).
There are significant differences in the number of cat-
egories in which the geriatrician, outpatient pharmacist, 
and CDSS noted remarks. That is, the CDSS (1.8 ± 0.8 vs. 
0.9 ± 0.9, p < 0.001) and outpatient pharmacist (1.8 ± 0.8 vs. 
0.9 ± 0.9, p < 0.05) both noted remarks in more categories 
than the geriatricians. Regarding the specific categories, 
the CDSS provided more remarks on ‘double medication’, 
‘dosage problem’ and ‘contraindication/interaction/adverse 
effects’ than the geriatrician did (p < 0.050), while the geri-
atrician provided more remarks on ‘medication without indi-
cation’ than the CDSS did (p < 0.001). The number of cat-
egories in which the outpatient pharmacist and CDSS noted 
remarks did not differ significantly (1.8 ± 0.8 vs. 1.8 ± 0.8, 
p = 0.458). However, the CDSS did note significantly more 
remarks in the ‘contraindication/interaction/adverse effects’ 
and ‘therapeutic drug monitoring’ category than the out-
patient pharmacist, while the outpatient pharmacist noted 
more remarks than the CDSS in the ‘indication without 
medication’ and ‘medication without indication’ categories 
(p ≤ 0.007) (Table 1).
The three categories in which geriatricians reported 
remarks most commonly were ‘medication without indica-
tion’, ‘indication without medication’, and ‘contra-indica-
tion/interaction/adverse effect’. Analysis of the content of 
remarks in the ‘indication without medication’ category 
shows that mostly vitamins, analgesics, laxatives, and diu-
retics in patients with congestive heart failure were reported 
as missing medication. On the other hand benzodiazepines, 
betahistin, opiates and antihistamines frequently emerged as 
‘medication without indication’. In the ‘contra-indication/
interaction/adverse effect’ category, antihypertensive agents 
and non-steroidal-anti-inflammatory drugs (NSAIDs) were 
identified particularly as problem-causing medication.
The most commonly reported remarks by the outpa-
tient pharmacist were on ‘indication without medication’, 
‘medication without indication’ and ‘dosage adjustment’. 
Adequate pain medication, vitamin D, and calcium supple-
mentation in case of insufficient dairy intake were advised 
in ‘indication without medication’. In contrast to the geri-
atricians, the largest share of remarks within the ‘medication 
without indication’ category concerns PPIs and a smaller 
share of betahistin and antihistamines. Finally, dosage 
adjustment is recommended especially for blood-glucose-
lowering-agents and statins.
Besides remarks in the seven categories, the outpa-
tient pharmacist focused on efficiency of medication pre-
scriptions, drug adherence, use of OTC medications, and 
presence of a medication organizer or blister pack. These 
remarks are not included in Table 1. In this study, in 5.6% 
of the prescriptions there was a less expensive alternative. 
Drug adherence was assessed ‘well’ in 72.2% of the patients. 
Just over half (51.9%) of the patients indicated use of OTC 
medications (mostly vitamins and analgesics). A medica-
tion organizer or blister pack was present in 57.4% of the 
patients. The number of medications patients indicated to 
use, compared to the number in their medication profile, 
only corresponded in 29.6%.
Most of the CDSS reports are coded ‘green’ (85.6%), 
leaving the remainder ‘red’ (14.4%). This implies that most 
reports do not require prompt action of the physician, but 
in approximately one out of every seven patients, there are 
potential hazards. Most CDSS reports were on ‘contraindi-
cations/interactions/adverse effects’ with particular remarks 
on the use of opiates without laxatives, use of metformin in 
renal failure and use of tricyclic antidepressant combined 
with opioids or calcium antagonists. In “indication without 
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medication”, the majority of reports was on use of PPIs in 
concomitant use of ASA.
Figure 1 shows in what percentage of patients a certain 
number of remarks was reported in one of the seven catego-
ries (also see “Appendix 2”).
Discussion
Different perspectives in medication review
This study showed that multiple ways of medication review 
lead to different perspectives. First, a lower total of remarks 
was noticed by the geriatrician, compared with the outpa-
tient pharmacist and the CDSS. This probably has to do with 
the fact that the geriatrician was not specifically instructed 
to perform a medication review and the outpatient pharma-
cist was (instruction bias). In addition the geriatrician has 
limited time to take a patient’s history, perform a physical 
examination, interpret additional diagnostics and discuss a 
treatment plan. Limited time has previously been mentioned 
as one of the most important constraints in performing medi-
cation reviews [25]. It is questionable whether more reports 
by the outpatient pharmacist and more CDSS alerts lead to 
more clinically relevant reports. Despite the lower number of 
reports from the geriatricians, these all had clinical relevance 
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Fig. 1  The number of remarks per category (% of patients)
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as evaluated by an independent geriatrician. As a conse-
quence of a standardized review guideline, there were no dif-
ferences in the number of remarks between the geriatricians.
Moreover, the geriatricians mainly focused on ‘indica-
tion without medication’, ‘medication without indication’ 
and ‘contra-indication/interaction/adverse effect’, whilst 
the outpatient pharmacist focused on these first two and 
‘dosage problem’. Regarding ‘indication without medica-
tion’ the similarities between the geriatrician and outpatient 
pharmacist include prescribing adequate pain-medication 
and vitamin D. The geriatrician focused on specific medical 
conditions such as congestive heart failure, whereas the out-
patient pharmacist did on general problems such as insuffi-
cient dairy intake. The differences in nature and scope of the 
remarks could be explained by educational differences and 
clinical judgement on a different level by the geriatrician. 
Overall, all remarks in this category from both the geriatri-
cian and outpatient pharmacist seemed clinically relevant.
Both the geriatricians and outpatient pharmacist con-
sidered betahistin and antihistamines as ‘medication with-
out indication’. This is of particular interest because of the 
anticholinergic effects and potential adverse events associ-
ated with the use of antihistamines [26]. There was however 
a clear difference between both groups, as the outpatient 
pharmacist emphasizes that PPIs are used too often. Previ-
ous studies have shown that the use of PPIs amongst older 
patients is high and often inappropriate, and could cause 
potential harm [27]. Perhaps pharmacists are more aware 
of this problem, as adding a pharmacist to a medication 
review team more often causes de-prescribing of PPIs [28, 
29]. However, the impact of de-prescribing PPIs on clinical 
outcomes is still not clear [29]. Lastly, the outpatient phar-
macist had more remarks on ‘dosage problems’, possibly by 
a greater emphasis on and knowledge of pharmacokinetics.
Pharmacist‑provided medication review
In addition, the outpatient pharmacist provided informa-
tion on efficiency of medication prescriptions, drug adher-
ence, use of OTC medications, and presence of a medica-
tion organizer or blister. From an economic perspective, 
given the rising health-care costs in the Netherlands [30], 
it is interesting to discuss less expensive alternatives for 
medication. In this study, in 5.6% there was a less expen-
sive alternative, suggesting that there already is emphasis 
on efficiency when prescribing medication, although it still 
provides possible cost reduction. Drug adherence was docu-
mented as ‘well’ in 72.2% of the patients, while just over 
half (57.4%) of the patients used a medication organizer or 
blister pack. Previous studies documented low drug adher-
ence, particularly in chronic conditions, and adherence in 
such case is estimated to average 50% [31–33]. Despite the 
low number of reliable trials, some studies showed trends to 
improved adherence whilst using medication organizers or 
blister packs [34]. Adequate drug adherence is central to suc-
cessful treatment of underlying diseases as non-adherence 
could lead to potential harm. This advocates focus on drug 
adherence during medication review and shows one of the 
benefits of including a pharmacist in this process. Overall, 
the pharmacist seems to have an important role in areas of 
medication safety, efficiency and drug adherence. Although 
previous literature showed neutral [35] and favourable [20, 
36] evidence towards clinical and economical outcomes of 
pharmacist-provided medication review, we advocate phar-
macist–geriatrician collaboration.
Clinical Decision Support System
Focusing on the CDSS, there is particular potential in 
reviewing ‘contraindications/interactions/adverse effects’, 
as it is a system based on clinical rules. These rules, that 
include the STOPP/START criteria are useful in identify-
ing PIP [37, 38]. Although most of the CDSS reports did 
not require prompt action from the physician, there were 
potential hazards in 14.4% of the medication profiles. The 
CDSS could therefore offer concrete and systematic ways 
of improving (de)prescribing medication and medication 
safety. Moreover, this set of clinical rules can be updated 
continuously and provides guidance to physicians working 
with older patients and polypharmacy. The disadvantage of 
CDSSs is the absence of clinical judgment and the fact that 
clinical rules apply at population level but not always on the 
individual.
Joint medication review
Overall, there are pros and cons that arise from medication 
review performed by a geriatrician, outpatient pharmacist 
and CDSS. Because each reviewer has its qualities and dis-
advantages, an integrated multidisciplinary approach seems 
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most desirable. Regardless of the way of medication review, 
prior research advocates interprofessional collaboration to 
achieve better clinical and economic outcomes [39]. One 
possible approach is using the CDSS in preparation of an 
outpatient visit and then have a (partly) joint geriatrician-
pharmacist consultation. Of course, this would require time 
investment in preparation of consultations and less time for 
other clinical activities. On the other hand using the CDSS 
prior to consultations could possibly save time during medi-
cation review. Another approach is an outpatient clinic spe-
cialized in polypharmacy with joint geriatrician-pharmacist 
consultation, but this would only be feasible for a limited 
number of patients. Our future aim is a clear instrument 
for medication review with the least time investment and 
the greatest impact on clinical and economic outcomes. So 
far, to our knowledge, no big randomized trials have been 
conducted that focus on the effect of medication review in 
non-hospitalized older patients on long-term clinical and 
economic outcomes. The potentially beneficial effects of 
medication review or pharmacological intervention [40, 41] 
therefore require further research.
Limitations
First of all, the outpatient pharmacist only reviewed a quar-
ter of all medication profiles due to logistical challenges. 
Because patients were seen at different locations, it was not 
feasible for the outpatient pharmacist to be present at both. 
On the other hand, these patients were selected randomly 
and all statistical analyses were performed with paired 
T-tests in an attempt to correct this. Second, the geriatri-
cians were not instructed specifically to perform a medica-
tion review and the outpatient pharmacist was. As a result, 
the number of remarks is not entirely comparable. Finally, 
this is a descriptive study, so no statements can be made 
on effects of medication review on clinical or economical 
outcomes.
Conclusion
Medication review by geriatricians mainly focuses on 
clinically relevant problems for which medication should 
be initiated or discontinued. Evaluation by an outpatient 
pharmacist provides additional information on efficiency of 
prescriptions and drug adherence, that could reduce increas-
ing health care costs and improve quality of care. The CDSS 
identified potential and therefore preventable hazards in 14% 
of the medication profiles. Because medication review per-
formed by a geriatrician, outpatient pharmacist, and CDSS 
provides different insights it should be combined to create 
a more comprehensive report on medication profiles. How-
ever, further research is required to determine the effects on 
clinical and economic outcomes.
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Appendix 1
ATC 
code
Percent-
age of 
patients 
using 
medica-
tion (%)
ATC 
code
Percent-
age of 
patients 
using 
medica-
tion (%)
ATC 
code
Percentage 
of patients 
using 
medication 
(%)
A02A 1 B03B 12 M01 8
A02B 59 B03X 0.5 M04 6.5
A03 2 C01 23.5 M05 13.5
A04 1 C02 2.5 N02A 18.5
A05 0 C03 42 N02B 22
A06 23.5 C07 41 N03 6.5
A07 1 C08 18.5 N04 3.5
A10A 7.5 C09 48 N05A 4.5
A10B 18.5 C10 44 N05C 24.5
A11 42 D 10.5 N06A 18
A12 24.5 G 13.5 N06D 3
B01 64 H 13.5 R 17
B02 1 H02 6 S 13.5
B03A 3.5 J 2 OTHER 11.5
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MEDICATION USE CATEGORIZED TO ATC 
CODE
Percentage (%)
Definition of ATC codes
A02A antacids
A02B drugs for peptic ulcer and gastro-esophageal reflux disease 
(protonpumpinhibitors, H2 receptor antagonists)
A03 drugs for functional gastro-intestinal disorders
A04 anti-emetics and anti-nauseants
A05 bile and liver therapy
A06 drugs for constipation
A07 antidiarrheals, intestinal anti-inflammatory/anti-infective agents
A10A insulins and analogues
A10B blood glucose lowering drugs excl. insulins
A11 vitamins
A12 mineral supplements
Definition of ATC codes
B01 antithrombotic agents
B02 antihemorrhagics (e.g. vitamin K)
B03A iron preparations
B03B vitamin B12 and folic acid
B03X other anti-anemic preparations
C01 cardiac therapy
C02 anti-hypertensives
C03 diuretics
C07 beta blocking agents
C08 calcium channel blockers
C09 agents acting on the renin–angiotensin system
C10 lipid modifying agents
D dermatologicals
G genito-urinary system and sex hormones
H systemic hormonal preparations, excl. sex hormones and insulins
H02 corticosteroids for systemic use
J anti-infectives for systemic use
M01 anti-inflammatory and anti-rheumatic products
M04 anti-gout preparations
M05 drugs for treatment of bone disease
N02A opioids
N02B other analgesics and antipyretics
N03 anti-epileptics
N04 anti-Parkinson drugs
N05A antipsychotics
N05C hypnotics and sedatives
N06A antidepressants
N06D anti-dementia drugs
R respiratory system
S sensory organs
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Appendix 2
Categories of remarks
No. of 
remarks
Category
Indication with-
out medication
Medication with-
out indication
Contra-indica-
tion/interaction/
side-effect
Dosage problem Double medica-
tion
Incorrect medi-
cation
Therapeutic 
drug monitor-
ing (TDM)
Geriatrician (n = 200)
 0 98 (49%) 173 (86.5%) 176 (88%) 173 (86.5%) 200 (100%) 198 (99%) 199 (99.5%)
 1 66 (33%) 19 (9.5%) 15 (7.5%) 24 (12%) – 2 (1%) 1 (0.5%)
 2 27 (13.5%) 5 (2.5%) 5 (2.5%) 3 (1.5%) – – –
 3 8(4%) 1 (0.5%) 3 (1.5%) – – – –
 4 1 (0.5%) 1 (0.5%) 1 (0.5%) – – – –
 5 – 1 (0.5%) – – – – –
Outpatient pharmacist (n = 54)
 0 12 (22.2%) 29 (53.75%) 40 (74.1%) 41 (75.9%) 53 (98.1%) 54 (100%) 54 (100%)
 1 20 (37%) 16 (29.6%) 12 (22.2%) 9 (16.7%) 1 (1.9%) – –
 2 17 (31.5%) 9 (16.7%) 2 (3.7%) 2 (3.7%) – – –
 3 3 (5.6%) – – 2 (3.7%) – – –
 4 2 (3.7%) – – – – – –
 5 – – – – – – –
CDSS (n = 197)
 0 116 (58.9%) 197 (100%) 6 (3%) 146 (74.1%) 196 (99.5%) 197 (100%) 161 (81.7%)
 1 49 (24.9%) – 52 (26.4%) 37 (18.8%) 1 (0.5%) – 36 (18.3%)
 2 13 (6.6%) – 21 (10.7%) 10 (5.1%) – – –
 3 18 (9.1%) – 28 (14.2%) 4 (2%) – – –
 4 – – 24 (12.2%) – – – –
 5 1 (0.5%) – 23 (11.7%) – – – –
 ≥ 5 – – 43 (21.8%) – – – –
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